Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Roche, Catalent
Roche CEO says Novo's Catalent buyout 'could be a problem' for smaller drugmakers
The groups behind the letter alleged that Novo Nordisk’s plant purchases could hinder not only the Danish drugmaker’s chief commercial rival, Eli Lilly, but also companies like Viking Therapeutics, Pfizer, Roche and AstraZeneca, who are working on their own metabolic offerings.
Roche CEO says antitrust regulators should block Catalent sale to Novo Foundation
The CEO of Swiss pharmaceuticals behemoth Roche (OTCQX:RHHBY) said he believes antitrust regulators should not allow Novo Nordisk Foundation's to purchase Catalent (NYSE:CTLT). "It's not a problem for us,
Roche comes out against allowing takeover of drug manufacturer Catalent
The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by Novo Nordisk's controlling shareholder, citing harm to industry peers.
Roche CEO Urges FTC to Block Novo Nordisk's Acquisition of Catalent
Roche CEO Urges FTC to Block Novo Nordisks Acquisition of Catalent Roches CEO, Thomas Schinecker, has called on authorities to prevent Novo Nordisks controlling shareholder, Novo Holdings, from acquiring contract
BioSpace
5h
Why It’s OK to Talk About Catalent’s Pending Buyout by ‘Novo’
The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of Catalent currently under FTC review—ultimately send proceeds to the Novo ...
STAT
26m
Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions
STAT's Readout LOUD podcast discusses Pfizer's woes, explains RFK Jr.'s 'MAHA' campaign, and mulls the latest about the Novo ...
3d
on MSN
Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout
Catalent CEO Alessandro Maselli said on Monday he will remain at the helm of the U.S.-based contract drugmaker after it is ...
devdiscourse
5h
Pharmaceutical Shifts and Health Innovations: A Global Perspective
Current health news covers Roche's opposition to Catalent's takeover, cost analysis of weight-loss drugs like Wegovy, U.S.
STAT
3d
Catalent tries to reassure customers about its deal with Novo Holdings
Catalent, a leading contract drug manufacturer, issued an open letter Monday to reassure customers that a proposed $16.5 ...
6d
Consumer groups ask FTC to block Novo Holdings-Catalent deal
U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, ...
FiercePharma
6d
Novo Holdings' $16.5B Catalent buyout in crosshairs as consumer groups ask FTC to block the deal
Novo Holdings is encountering more resistance as it aims to close its $16.5 billion acquisition of pharma manufacturing giant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Roche
Federal Trade Commission
Alessandro Maselli
Thomas Schinecker
Feedback